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Abstract: In chronic kidney disease (CKD), the first cause of mortality is cardiovascular disease
induced mainly by vascular calcification (VC). Recently, iron-based phosphate binders have been
proposed in advanced CKD to treat hyperphosphatemia. We studied the effect of iron citrate (iron)
on the progression of calcification in high-phosphate (Pi) calcified VSMC. Iron arrested further
calcification when added on days 7–15 in the presence of high Pi (1.30 ± 0.03 vs 0.61 ± 0.02; OD/mg
protein; day 15; Pi vs Pi + Fe, p < 0.01). We next investigated apoptosis and autophagy. Adding iron
to high-Pi-treated VSMC, on days 7–11, decreased apoptotic cell number (17.3 ± 2.6 vs 11.6 ± 1.6;
Annexin V; % positive cells; day 11; Pi vs Pi + Fe; p < 0.05). The result was confirmed thorough
analysis of apoptotic nuclei both in VSMCs and aortic rings treated on days 7–15 (3.8 ± 0.2 vs 2.3 ± 0.3
and 4.0 ± 0.3 vs 2.2 ± 0.2; apoptotic nuclei; arbitrary score; day 15; Pi vs Pi + Fe; VSMCs and aortic
rings; p < 0.05). Studying the prosurvival axis GAS6/AXL, we found that iron treatment on days
9–14 counteracted protein high-Pi-stimulated down-regulation and induced its de novo synthesis.
Moreover, iron added on days 9–15 potentiated autophagy, as detected by an increased number of
autophagosomes with damaged mitochondria and an increase in autophagic flux. Highlighting the
effect of iron on apoptosis, we demonstrated its action in blocking the H2O2-induced increase in
calcification added both before high Pi treatment and when the calcification was already exacerbated.
In conclusion, we demonstrate that iron arrests further high Pi-induced calcium deposition through
an anti-apoptotic action and the induction of autophagy on established calcified VSMC.
Keywords: iron; vascular calcification; apoptosis; VSMC; phosphate; autophagy
1. Introduction
Vascular calcification (VC) is common in advanced chronic kidney disease (CKD), and is associated
with poor cardiovascular (CV) outcomes [1]. The pathogenesis of VC is multifactorial and incompletely
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understood. CKD patients are at risk of VC because of multiple risk factors. High phosphate (Pi)
levels are associated with a high risk of VC and CV disease in the general population and, in particular,
in CKD patients [2]. It has been clearly demonstrated that high Pi induces vascular smooth muscle cells
(VSMCs) osteoblastic differentiation [3]. Beside high Pi, other factors potentially cause the phenotypical
change of VSMCs into an osteoblast-like cell, such as high total body burden of calcium (Ca) and Pi,
low levels of circulating and locally-produced inhibitors, impaired renal excretion, and CKD-MBD
(Mineral Bone Disorder) treatments [4].
Commonly, treatment of hyperphosphatemia requires a multimodal approach:
Dialysis, dietary restriction of Pi intake (i.e., food with low Pi content, balancing sufficient
protein intake and restricting Pi intake, counteracting “hidden” phosphate due to insufficient labelling
of processed food), and the prescription of Pi binders [5]. Considerations for the choice of Pi
binder may include age, gender, diabetes, low bone turnover, vascular and/or valvular calcification,
and inflammation [6]. Recently, two new iron-based Pi binders have become available to dialysis
patients to treat hyperphosphatemia [7]. In addition, we demonstrated: (1) the effect of iron citrate
in preventing calcification in an in vitro model of high Pi-induced VC, finding that iron reduces Ca
deposition through the prevention of apoptosis and the enhancement of autophagy [8]; (2) that iron is
able to both prevent and partially revert extracellular matrix osteo-chondrogenic shifts induced by high
Pi treatment acting on elastinolysis, fibrosis, mucins synthesis, and glycolytic VSMC metabolism [9].
Although the effect of iron citrate on the progression of calcification in established calcified VSMCs
has already been presented in a previous study of our research group [8], the aim of the present set
of data is to better elucidate the mechanisms of the direct effect of iron citrate on the progression of
calcification in established high Pi-calcified VSMCs.
2. Results
2.1. Iron Citrate Arrests High Pi-Induced Calcium Deposition in Established Calcified VSMCs
Ferric citrate was used in an experimental setting of established calcified VSMCs to evaluate the
effect of iron on the progression of calcification. In this setting, we added 50 µM ferric citrate (Fe) seven
days after VSMCs had been challenged with 5 mM Pi (high Pi), and treated them with Fe and high
Pi for the following eight days, i.e., up to day 15. As shown in Figure 1A, the therapeutic addition
of Fe completely blocked the additional calcification induced by high Pi. In fact, from days 7 to 15,
there was a significant progression of calcium deposition in high Pi-treated samples (0.57 ± 0.02 vs
1.30 ± 0.03, OD/mg protein; day 7 vs day 15, p < 0.01, Figure 1A), which were reduced by 95% by eight
days’ treatment with 50 µM Fe (1.30 ± 0.03 vs 0.61 ± 0.02, OD/mg protein; day 15 Pi vs Pi + Fe days
7–15, p < 0.01, Figure 1A) to the same extent of calcification on day 7 (0.57 ± 0.02 vs 0.61 ± 0.02, OD/mg
protein; day 7 Pi vs Pi + Fe days 7–15, ns, Figure 1A). Iron influenced not only calcium deposition but
also VSMC viability, as shown by the protein content in samples treated with iron from days 7 to 15
compared to high Pi-challenged samples on day 15 (3.55 ± 0.09 vs 3.19 ± 0.03, mg protein; Pi + Fe days
7–15 vs day 7 Pi, p < 0.05, Figure 1B)
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Figure 1. Effect of therapeutic addition of ferric citrate on high Pi-induced progression of calcification.
Rat VSMCs were cultured with 5 mM Pi in a calcification medium for up to 15 days. (A) The addition
of 50 µM Fe to the already calcified VSMCs from days 7 to day 15 was able to completely block
additional high Pi calcium deposition (* p < 0.01). Calcium deposition was measured and normalized
by cellular protein content. Data are presented as mean ±SE of five experiments in triplicate. (B) The
addition of 50 µM Fe on already calcified VSMCs from days 7 to day 15 was able to improve VSMC
viability, measured as the total protein content (# p < 0.05). Data are presented as the mean ±SE
of five experiments in triplicate. (C) Ca deposition was visualized at a light microscopic level by
Alizarin Red staining. Red indicates Ca deposits. The figure shows that treatment from days 7 to 15 of
calcification with 50 µM Fe blocks calcium deposition that is comparable to seven. Magnification 200×.
Representative results of one of the three different experiments.
Evaluating the size and number of calcium granules, as expected, there were calcified deposits
with different sizes after seven days of high Pi challenge that increased, becoming a confluent structure
of deposits on the cellular layer on day 15 (0.8 ± 0.1 vs 2.7 ± 0.1; day 7 vs day 15; a.s.; p < 0.01; Figure 1C).
Treatment with Fe from days 7 to 15 of calcification blocked the additional granule deposition with no
detectable difference in the size or quantity of the granules compared with day 7 of calcification (day of
start of iron treatment) (0.8 ± 0.1 vs 1.2 ± 0.2; Pi day 7 vs Pi + Fe days 7–15; a.s.; ns; Figure 1C).
2.2. Ferric Citrate Counteracts High Pi-Induced Apoptosis in Calcified VSMCs
The effect of ferric citrate on apoptosis was studied by the detection of the early marker
phosphatidylserine via binding with annexin V, by nuclei fragmentation with TUNEL, by the effect on
H2O2 exacerbation of high Pi-induced calcification and by the modulation of the prosurvival pathway
GAS6/AXL.
The treatment of calcified VSMCs from days 7 to 11 of calcification with iron was able to
significantly decrease the percentage of annexin V positive cells, and thus apoptosis. Both 7 and 11 days
of high Pi challenge induced a significant increase in apoptotic cell number compared to controls (6.0
± 1.4 vs 12.3 ± 2.1 day 7, 6.6 ± 1.5 vs 17.3 ± 2.6 day 11, ctr vs Pi, annexin V% positive cells; p < 0.01,
Figure 2A,B). Treatment for four days with 50 µM Fe, and from days 7 to 11 with calcification, was able
to significantly block the increase in high Pi-induced apoptotic cell number, i.e., by 53% (17.3 ± 2.6
vs 11.6 ± 1.6; day 11; Pi vs Pi + Fe; annexin V% positive cells; p < 0.05; Figure 2A,B). In parallel,
Fe treatment from days 7 to 11 of calcification significantly blocked additional high Pi-induced calcium
deposition, i.e., similarly to the 7–15-day experimental protocol (74%; Figure 2C,D).
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Figure 2. Effect of the therapeutic addition of ferric citrate on high Pi-induced progression of apoptosis.
Rat VSMCs were cultured with 5 mM Pi in a calcification medium for up to 11 days. Apoptosis was
evaluated by flow cytometry detection by annexin V and 7-amino-actinomycin D (7-AAD) staining.
(A) Representative dot plots of 7-AAD versus annexin-V-PE. VSMC were left untreated (control)
or were treated with Pi or Pi + Fe. The lower left quadrant contains the vital (double negative)
population; the lower right contains the early apoptotic (annexin V+/7-AAD−) population; the upper
right contains the late apoptotic/necrotic (annexin V+/7-AAD+) population; and the upper left contains
the prenecrotic (annexin V−/7-AAD+) population. (B) Average percentage of early apoptotic and
late apoptotic/necrotic cells. Treatment with 50 µM Fe from days 7 to 11 of calcification was able
to significantly block the increase in high Pi-induced Annexin V positive cells (# p < 0.05, ns: No
significance). Data are presented as mean ±SE of four different experiments. (C) The addition of 50 µM
Fe on already calcified VSMCs from days 7 to day 11 was able to block further high Pi-induced calcium
deposition (* p < 0.01). Calcium deposition was measured and normalized by cellular protein content.
Data are presented as the mean ±SE of four experiments in triplicate. (D) Ca deposition was visualized
at a light microscopic level by Alizarin Red staining. Red indicates high Pi-dependent Ca deposits.
The images show that treatment from days 7 to 11 of calcification with 50 µM Fe blocked calcium
deposition with results comparable to those of day 7. Magnification 200×. Representative result of one
of four different experiments.
We performed TUNEL staining to evaluate a late marker of apoptosis as nuclei fragmentation.
From the images in Figure 3, it is possible to detect only sporadic apoptotic fragmented nuclei as
a red signal in control VSMCs and aortic rings. Seven days of high Pi treatment induced apoptosis
that progressed to diffuse fragmentation in almost all cell nuclei evaluated after 15 days of challenge,
both in VSMCs and aortic rings (Figure 3A,B). Iron addition when calcification was established, after 7
days of high Pi treatment, induced a block in the progression of apoptosis. In fact, by analyzing on day
15 of high Pi challenge the apoptotic nuclei both in VSMCs and aortic rings treated with 50 µM Fe from
day 7 to 15, there was significantly less apoptosis compared to that on day 15 (3.8 ± 0.2 vs 2.3 ± 0.3
and 4.0 ± 0.3 vs 2.3 ± 0.2; apoptotic nuclei; arbitrary score; day 15; Pi vs Pi + Fe; VSMCs and aortic
rings, respectively; p < 0.05, Figure 3B,C), with no significant difference compared to day 7 (2.2 ± 0.2
vs 2.3 ± 0.3 and 2.0 ± 0.2 vs 2.3 ± 0.2; apoptotic nuclei; arbitrary score; Pi day 7 vs Pi + Fe days 7–15;
VSMCs and aortic rings, respectively; ns Figure 3B,C).
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Figure 3. Effect of therapeutic addition of ferric citrate on 15 days of high Pi-induced progression of
apoptosis in aortic rings and VSMCs. Rat VSMCs and aortic rings were cultured with high Pi (5 and
3 mM, respectively) in a calcification medium for up to day 15. (A,D) Apoptosis was visualized by
TUNEL staining; (B,C): Semi-quantitative analysis of staining data. (A,D): Therapeutic addition of
50 µM Fe was able to block high Pi-induced nuclear apoptotic red signal progressive increase from
day 7 to day 14, both in VSMCs and within the aortic wall (inset). (B,C) The addition of 50 µM Fe
to already calcified VSMCs and aortic rings was able to protect the vessel from the high Pi-induced
nuclei fragmentation detectable as red signals. Data are presented as the mean ±SE of at least two
experiments in triplicate. (# p < 0.05). Magnification: Panel A 40×, panel D 20×, inset 100×.
In order to evaluate the effect of iron on apoptosis-induced calcification, we treated VSMCs with
high Pi and a proapoptotic stimulus (H2O2) which was able to increase calcium deposition. Treatment
with either 0.6 or 0.8 mM H2O2, starting on day 0 of calcification, resulted in +37% and +74% increases
in calcium deposition, as expected (0.49 ± 0.02 and 0.62 ± 0.03 vs 0.36 ± 0.02; 0.6 and 0.8 mM H2O2
+ Pi vs Pi, day 7; OD/mg protein; p < 0.01, Figure 4). Next, we added 2 and 5 µM iron, the first as a
non-effective concentration and the second yielding a 60% inhibition of calcification in this experimental
setting (Figure 4). Five micromolar Fe was able to completely abolish the H2O2-induced exacerbation
of high Pi-driven calcium deposition (0.49 ± 0.02 vs 0.17 ± 0.02; 0.6 mM H2O2 + Pi vs 5 µM Fe + 0.6
mM H2O2 + Pi; and 0.62 ± 0.03 vs 0.18 ± 0.01; 0.8 mM H2O2 + Pi vs 5 µM Fe + 0.8 mM H2O2 + Pi; day
7; OD/mg protein; p < 0.01, Figure 4). Surprisingly, 2 µM Fe, that was ineffective on high Pi-induced
calcium deposition, was also able to completely abolish the H2O2-induced worsening of calcification
(0.49 ± 0.02 vs 0.39 ± 0.02; 0.6 mM H2O2 + Pi vs 2µM Fe + 0.6 mM H2O2 + Pi; and 0.62 ± 0.03 vs
0.35 ± 0.02; 0.8 mM H2O2 + Pi vs 2 µM Fe + 0.8 mM H2O2 + Pi; day 7; OD/mg protein; p < 0.01, Figure 4).
We then chose a 0.8 mM H2O2 concentration to test whether iron was able to stop apoptosis-induced
calcium deposition when calcification was already established. Adding H2O2 from day 7 to day 14
resulted in an exacerbation of calcification (1.25 ± 0.04 vs 1.37 ± 0.03; Pi vs 0.8 mM H2O2 + Pi day
7–14; day 14; OD/mg protein; p < 0.05, Figure 5). Treating VSMCs from day 7 to day 14 with 20µM Fe
resulted in a block of not only high Pi increase in calcification (1.25 ± 0.04 vs 0.84 ± 0.03; Pi vs Pi + Fe
day 7–14; day 14; OD/mg protein; p < 0.01, Figure 5), but also in an apoptosis-induced worsening of
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high Pi caused by H2O2 (1.37 ± 0.03 vs 0.96 ± 0.05; H2O2 + Pi day 7–14 vs Fe + H2O2 + Pi day 7–14;
day 14; OD/mg protein; p < 0.01, Figure 5).
We next evaluated the prosurvival pathway GAS6/AXL that, as expected, was down-regulated
at both 9 and 15 days of calcification, with a significant decrease in protein expression (−8.45% and
−8.55% GAS6; −14.29% and −16,27% AXL; Pi day 9 and 15 respectively, compared to control; p < 0.05;
Figure 6). Treating calcified VSMCs from day 9 to day 15 of calcification with 50 µM Fe in the presence
of high Pi-challenge resulted in a significant induction of de novo synthesis of the two proteins GAS6
and AXL that reached levels not statistically different from control samples (+6.90% GAS6; +12.66%
AXL; Pi + Fe compared to Pi day 9; p < 0.05; Figure 6).
Figure 4. Effect of prophylactic addition of ferric citrate on H2O2 worsening of high Pi-induced
calcification. Rat VSMCs were cultured with 4.5 mM Pi in the calcification medium for up to 7 days.
(A) Pretreatment with H2O2 was able to worsen high Pi-induced calcium deposition. Iron addition
(2 and 5 µM) completely prevents H2O2 worsening of high Pi calcification. Calcium deposition was
measured and normalized by cellular protein content. Data are presented as the mean ±SE of three
experiments in triplicate. (# p < 0.05; * p < 0.01). (B) Ca deposition was visualized at light microscopic
level by Alizarin Red staining. Red color indicates Ca deposits. The figure shows images of calcium
deposition modulation by iron in the presence of H2O2 in the experimental conditions indicated.
Magnification 200×. Representative result of one of three different experiments.
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Figure 5. Effect of therapeutic addition of ferric citrate on H2O2 worsening of high Pi-induced
calcification. Rat VSMCs were cultured with 4.5 mM Pi in a calcification medium for up to 14 days.
(A) The addition of 20 µM Fe on already calcified VSMCs from day 7 to day 14 was able to completely
block additional high Pi calcium deposition induced by proapoptotic molecule H2O2 (0.8 mM) treatment
during the same period. Calcium deposition was measured and normalized by cellular protein content.
Data are presented as the mean ±SE of three experiments in triplicate. (# p < 0.05; * p < 0.01). (B) Ca
deposition was visualized at a light microscopic level by Alizarin Red staining. Red indicates Ca
deposits. The figure shows images of calcium deposition modulation by iron in the presence of H2O2
in the experimental conditions indicated. Magnification 200×. Representative result of one of three
different experiments.
Figure 6. Effect of therapeutic addition of ferric citrate on the expression of the GAS6/AXL pathway
during the progression of high Pi-induced calcification. Rat VSMCs were cultured with 5 mM Pi in
a calcification medium for up to 15 days. A and C: GAS6 and AXL protein expression were analyzed
by western blot. Lane 1: Control day 9; lane 2: 5 mM Pi day 9; Lane 3: Control day 15; lane 4: 5 mM Pi
day 15; lane 5: 5 mM Pi + 50 µM Fe from day 9 to day 15. Representative result of one of three different
experiments. B and D: Analysis of the intensity of the immunoblot bands of GAS6 and AXL normalized
for beta tubulin bands are shown. Therapeutic addition of 50 µM Fe stimulates the synthesis of both
GAS6 and the AXL protein, thereby inducing this prosurvival pathway. Data are presented as the mean
±SE of three different experiments (# p < 0.05).
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2.3. Ferric Citrate Induces Autophagy in Established Calcified VSMCs
Using electron microscopy, we analyzed the VSMC finding that in calcified conditions, there were
several partially- or completely-calcified mitochondria that lost the cristae structure which is typical of
functionally-intact mitochondria (Figure 7A–C; Figure 7B,D inset b). It has been demonstrated that high
Pi-induced calcification inhibits the autophagic process, and in fact, in 9 and 14 days’ calcified VSMCs,
a few or no autophagosomes were detectable within the cells, despite the many calcified mitochondria
(Figure 7B,D). Treating calcified VSMCs with 50 µM Fe from day 9 to day 14 of calcification induced
autophagosomes formation (Figure 7E inset b). In fact, together with the calcified mitochondria free in
the cytoplasm, it was possible to detect some of them rounded by a double layer membrane, which is
typical of autophagosome (Figure 7E inset b).
Figure 7. Effect of the therapeutic addition of ferric citrate on autophagosome formation during the
progression of high Pi-induced calcification. (A) Image a: Electron microscopy micrograph of an
ultra-thin section from control VSMCs on day 9; scale bar 2 µm.
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Image b: Enlargement of red boxed area in image a showing normal mitochondria (arrows); scale bar
200 nm. (B) Image a: Electron microscopy micrograph of an ultra-thin section from 5 mM Pi treated
VSMCs for 9 days; scale bar 1 µm. Image b: Enlargement of red boxed area in image a, arrows point
to calcified mitochondria; scale bar 500 nm. (C) Electron microscopy micrograph of an ultra-thin
section from control VSMCs on day 14 showing normal mitochondria (arrows); scale bar 200 nm. (D)
Image a: Electron microscopy micrograph of an ultra-thin section from 5 mM Pi treated VSMCs for 14
days; scale bar 1 µm. Image b: Enlargement of red boxed area in image a, arrows point to completely
calcified mitochondria; scale bar 500 nm. (E) Image a: Ultra-thin section from 5 mM Pi + 50 µM Fe
treated VSMCs from day 9 to day 14, arrows point to autophagic vacuoles; scale bar 200 nm. Image b:
Enlargement of the red boxed area in image a shows an autophagic vacuole with completely calcified
mitochondria inside; scale bar 100 nm. Image c: Arrowhead points to an autophagic vacuole with
completely calcified mitochondria inside, whereas arrows point to calcified mitochondria; scale bar
400 nm.
In order to confirm the electron microscopy observations, we studied the autophagic flux by
the analysis of the marker of the autophagosome light-chain 3-IIB (LC3IIβ). We compared the
LC3IIβ expression in samples with or without treatment with 25 µM chloroquine, an inhibitor of
autophagosome degradation (Figure 8A). Analyzing the difference of LC3IIβ expression between the
samples with and without chloroquine addition, we found that Pi challenge inhibited the autophagic
flux progressively from day 9 to day 14 of calcification, as expected (43.4 and 20.8 ∆ intensity area, Pi day
9 and 14, respectively; p < 0.05; Figure 8B). In contrast, treatment of calcified cells with 50 µM Fe from
day 9 to day 14 of calcification induced an autophagic flux that was significantly increased compared
to high Pi-treated samples on day 14 and comparable to controls (59.7, 20.8 and 75.6; ∆ intensity area,
ctr, Pi and Pi+Fe day 14, respectively; Pi + Fe vs Pia and Pi + Fe vs ctrb; a p < 0.05; b ns; Figure 8B).
This result confirms the induction of autophagy in samples therapeutically treated with 50 µM Fe.
Figure 8. Effect of therapeutic addition of ferric citrate on autophagic flux during the progression
of high Pi-induced calcification. Rat VSMCs were challenged with 5 mM Pi for up to 14 days. (A)
LC3IIB protein expression was detected by immunoblotting analysis in the absence or presence of ON
treatment with 25 µM chloroquine ‘C’ from day 8 or 13. Lane 1: Control day 9; lane 2: Control day 9 +
chloroquine; lane 3: 5 mM Pi day 9; lane 4: 5 mM Pi day 9 + chloroquine; lane 5: Control day 14; lane
6: Control day 14+chloroquine; lane 7: 5 mM Pi day 14; lane 8: 5 mM Pi day 14+chloroquine; lane 9:
5 mM Pi + 50 µM Fe from day 9 to 14; lane 10: 5 mM Pi + 50 µM Fe from day 9 to 14+chloroquine.
Representative result of one of three different experiments. (B) Graph of the immunoblot band intensity
is shown normalized for beta tubulin area intensity. Shaded bars represent different conditions in
presence of ON treatment with chloroquine. Empty rectangles indicate the autophagic flux. Data are
presented as the mean ±SE (# p < 0.05).
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3. Discussion
VC is a multifactorial process due to the pathological deposition of minerals in the vascular system.
Several causes have been identified in the pathogenesis of VC, such as an imbalance between pro- and
anti- calcific factors; osteo-chondrogenic differentiation of VSMCs induced by inflammation, lipids,
calcium and phosphate; apoptotic process; matrix degradation; and elastolysis [10].
In CKD, together with the traditional factors inducing VC, some nontraditional factors exist,
namely uremic milieu and hyperphosphatemia. It is accepted that among all of the pathophysiologic
mechanisms in CKD, VC is strongly associated with CV mortality, and it appears that high serum Pi
levels are the most likely culprit behind VC [11].
Many efforts have been made in recent years to try to properly investigate and elucidate the
mechanisms of high Pi-induced VC. The most in vitro-utilized approach is to study the effect of
different molecules on the prevention of VC through different aspects such as calcium deposition,
VSMCs osteoblastic transdifferentiation, apoptosis, elastolysis, matrix degradation, and authophagy.
Applying the prophylactic approach in vitro, we published a study on the effect of iron on VC,
demonstrating that ferric citrate prevents high Pi-induced calcium deposition by preventing apoptosis
and by the potentiation of authophagy [8]. Interestingly, we also found that iron acts on the extracellular
matrix osteo-chondrogenic shift induced by high Pi treatment, both preventing and blocking/partially
reverting it [9]. The interest in the action of iron on calcification is also legitimated by the recent clinical
use of this molecule as a Pi binder. In fact, two new Ca-free, iron-based P binders are now available to
treat hyperphosphatemia in CKD, namely iron citrate and sucroferric oxyhydroxide [7].
Trying to investigate the direct effect of iron on VC, in the present study, we evaluated the
effect of ferric citrate on high Pi-induced calcification mechanisms in established calcified VSMCs,
elucidating the data of the effects of iron on calcium deposition [8]. We performed an in vitro
therapeutic approach to evaluate how iron can modulate calcification in an established pathological
model of VC. The addition of ferric citrate to 7-day calcified VSMCs completely blocked additional
calcium deposition induced by high Pi in the following 8 days of treatment. This result is highly
surprising, considering that after 7 days of high Pi challenge, the VSMCs that received iron were
already transformed into simil-osteoblasts, and actively deposited calcium-phosphate crystals [8].
In contrast, in the prophylactic approach, when VSMCs receive high Pi and iron, their phenotype is
muscular, and iron may act on the prevention of high Pi-induced VC mechanisms. Thus, performing
experiments with the prophylactic and therapeutic administration of iron, we demonstrate that iron
can completely block calcium deposition regardless of the grade of high Pi-induced simil-osteoblastic
transformation of VSMCs.
Trying to elucidate the mechanisms responsible for this therapeutic action, we studied apoptosis
and autophagy, since we already demonstrated their involvement in the prevention of high Pi-induced
calcification [8]. Analyzing apoptosis in the early phase, we found that iron treatment for 4 days on
high Pi-calcified VSMCs blocked the progression of apoptosis with a number of total apoptotic cells
which was not statistically different from that at the beginning of the addition of iron. These data are
surprising if we consider that iron is added together with high Pi, and that in 11-day, high Pi-treated
VSMCs, apoptotic cell number increases. Thus, iron is able not only to prevent high Pi-induced
apoptosis, but also to delay and block the progression of apoptosis, even if the process is already started
and the apoptosis-inducing agent is present. Confirming the anti-apoptotic effect of iron are the data on
H2O2, a recognized proapoptotic agent. After 7 days of high Pi treatment, H2O2 induced a worsening
of calcification that was completely counteracted by iron. Interestingly, even a concentration of
iron of 2 µM, i.e., one that is ineffective in preventing high Pi calcification, was able to completely
prevent a H2O2-induced increase in calcium deposition. Moreover, iron is also effective at blocking
H2O2-induced exacerbation of calcification on already calcified VSMCs, demonstrating an iron
anti-apoptotic effect in our in vitro experimental model.
Study of the late stages of the apoptotic process by TUNEL confirms this concept. In fact,
increased apoptotic nuclei were detected during high Pi treatment with a massive release of fragmented
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apoptotic bodies at late time points [12]. Even if in this work only nuclear bodies were taken into account
in evaluating apoptosis, fragmented red dust, at the cytoplasmic level and in the extracellular matrix,
was detected. This kind of signal can be interpreted as fragmented apoptotic bodies excreted from
dying cells in the extracellular space and/or possibly taken up by phagocytic cells [13]. We decided to
evaluate only the nuclear fragmentation of nuclei during apoptotic death, but interestingly, the specific
increase of nuclear red signals consensually paralleled the increase of extra-nuclear apoptotic signals,
thus confirming the pattern of apoptosis during high Pi and Fe treatment.
We next investigated the GAS6/AXL prosurvival pathway, which has been shown to be affected by
high Pi treatment [13]. Our data confirmed the involvement of these proteins in the iron citrate protective
mechanism. In fact, we found an iron-induced positive modulation of GAS6/AXL synthesis. In our
previous study on prophylactic treatment with iron, we demonstrated a preventative action exerted by
iron on high Pi-induced GAS6/AXL down-regulation. Interestingly, therapeutic-added iron not only
protects by further high Pi-induced down-regulation of GAS6/AXL proteins, but strongly stimulates
their de novo synthesis, reactivating this prosurvival and anti-apoptotic pathway. Therefore, one of
the mechanisms by which iron citrate exerts its anti-apoptotic action could be the restoration of the
GAS6/AXL prosurvival axis. Apoptosis is a relevant process to VC. In fact, apoptotic cells and released
apoptotic bodies form a nidus for calcification, and increase the propensity of VSMCs to calcify after
calcium and phosphate treatment [14]. Apoptosis, in calcifying VSMCs, is driven mainly by calcium
rather than phosphate alone, as in our model. Nevertheless, a source of calcium is calcium phosphate
crystals that undergo lysosomal degradation by VSMCs, leading to very high intracellular calcium
levels and subsequent cell death, beginning a vicious cycle of progressive calcification [15].
In this study, we show that one of the mechanisms of high Pi-induced calcification, apoptosis,
can be reverted and counteracted by iron added therapeutically in vitro. These findings demonstrate
that iron has an anti-apoptotic effect in high Pi-stimulated VSMCs, independent of the grade of
calcification and simil-osteoblastic cell transformation.
Apoptosis is strictly linked to autophagy, and can be considered as a dramatic consequence of the
failure of autophagy to re-establish a positive balance for the cells evolving in survival. Since iron is
prophylactically able to modulate autophagy in high Pi-treated VSMCs, we investigated the autophagic
process. Autophagy is a highly-conserved cellular process which is responsible for the removal or
recycling of long-lived proteins and organelles aimed to give an alternative source of nutrients to cells
in conditions of either starvation or stress [16]. To some extent, autophagy can prevent the activation
of apoptotic pathways through the removal of damaged mitochondria [17], although, in some systems,
autophagy can enhance an apoptotic response [18]. It has been demonstrated that autophagy is
a protective phenomenon with respect of high Pi-induced calcification, playing a pivotal role in arterial
calcification [19]. We found that the therapeutic addition of iron was able to stimulate autophagy,
even in the presence of high Pi challenge on already calcified VSMCs. In fact, from day 9 to day 14 of
calcification, there was a significant reduction of autophagic flux, and treating cells in the same 6 days
with iron, even in presence of high Pi, resulted not only in the prevention of further autophagic flux
downregulation, but also in the re-induction of the autophagic process. These data were confirmed by
electron microscopy. In fact, at 9 days of calcification, there were many calcified mitochondria and
no or few autophagosomes, showing the degree of difficulty for the cells to remove these completely
damaged organelles. After 6 days of therapeutic iron treatment, on day 14 of calcification, there were
still many calcified mitochondria, but there were also autophagosomes filled with damaged organelles,
indicating that iron reactivates the autophagic process, helping cells to eliminate damaged mitochondria.
As demonstrated for apoptosis, also with respect to autophagy, the therapeutic addition of iron is able
to revert the high Pi-induced decrease of the autophagic flux, reactivating the autophagic process.
Iron is an oxidative agent and is rapidly stored by cells because of its potential toxic effect.
The addition of iron citrate may affect the red-ox state of high Pi-stimulated VSMCs, and a link between
oxidative stress and autophagy in different cellular models has been demonstrated. In fact, autophagy is
induced as a response to the toxic effect of reactive oxygen species (ROS), and contributes to clearing
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the cells of all irreversibly-oxidized biomolecules (proteins, DNA and lipids); this is why it can be
included in antioxidant and DNA damage repair systems [20]. The balance between ROS production
and cellular antioxidant mechanisms in high Pi-stimulated VSMCs has been poorly investigated.
Probably, a better understanding of oxidative stress/antioxidant defense processes in VC is needed
to determine whether iron’s oxidant nature is linked to its mechanism of action and to its effect on
autophagy and apoptosis. An important observation is that iron entry into cells induces ferritin
synthesis for the storage of this ion to prevent the Fenton reaction, which is dangerous for cell viability
due to the production of free radicals. Interestingly, there is evidence that the feroxidase activity of the
ferritin heavy chain can protect from both calcification [21,22] and apoptosis [23]. Thus, further studies
are needed to deeply investigate whether ferritin heavy chain feroxidase activity can account for the
block of calcium deposition and the anti-apoptotic and proautophagic effects of iron in our model of
therapeutic in vitro progression of high Pi-induced calcification.
In summary, we studied the effect of iron treatment on established calcified VSMCs,
and consequently, on the progression of calcification in vitro. We demonstrated that iron blocks
the progression of calcium deposition by affecting apoptosis and autophagy. In fact, iron citrate can
revert the high Pi-induced apoptotic process and re-induce autophagy; the combination of these two
effects is probably responsible for blocking the calcification progression. These findings, together with
the data on iron’s ability to partially revert the high Pi-induced osteo-chondrogenic shift of the VSMC
extracellular matrix, help to better elucidate the complex effects of iron and add a piece to the mosaic
of its action.
VSMCs are cells with some plasticity, and share their mesenchymal origin with osteoblasts.
This may explain why continuous exposition at high Pi levels induces a VSMC simil-osteoblastic
differentiation and their ability to deposit calcium phosphate crystals in the vasculature.
Nevertheless, we have already demonstrated that suspending the high Pi challenge for brief
periods is enough to significantly decrease calcium deposition, meaning that VSMCs can stop
the calcium deposition activity, even if already transformed, if the pro calcifying stimulus is
suspended, even temporally, at least in vitro [24]. Here we demonstrate that even if VSMCs are
already transformed and the procalcifying stimulus is present, reverting apoptosis and inducing
autophagy probably contribute to stopping calcium deposition. Taken together, these data suggest
that already transformed VSMCs are prone to stopping the calcium deposition process if calcification
mechanisms are adequately targeted.
From these in vitro data, we can conclude that iron can block the progression of calcification and,
in line with the iron effect on the extracellular matrix osteochondrogenic shift, we demonstrate that
some high Pi-induced processes can be reverted, not only prevented, in vitro. The importance of this
reversion concept is in the arrest of additional calcium deposition that is fundamental if we consider
the detrimental role of VC in CV disease and its association with increased mortality in CKD patients.
4. Materials and Methods
4.1. Materials
DMEM (high glucose, [4.5 g/L]), NaCl, FBS, and a BCA protein assay kit (Pierce, Rockford, IL,
USA) were purchased from Euroclone (Milan, Italy); Na3PO4, MgSO4, NaH2PO4, KH2PO4, and KCl
were purchased from Carlo Erba (Milan, Italy); ferric citrate, Trypsin-EDTA-Solution (T4174) and
Collagenasi type IA (C9891) were purchased from Sigma (St. Louis, MO, USA); the primary antibody
for Axl (sc-1097) and GAS6 (N-20 sc-1936) were purchased from Santa Cruz (Heidelberg, Germany);
the primary antibody for LC3-II was purchased from Cell Signalling (Danvers, MA, USA), and
the anti-rabbit secondary antibody was purchased from GeneTex (Irvine, CA, USA); the anti-goat
secondary antibody (ab6741) was purchased from Abcam (Cambrige, UK); Hepes Buffer Solution,
PVDF membrane Invitrogen/Applied Biosystem (Milan, Italy); PE Annexin V Apoptosis Detection Kit
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I (559763) was purchased from Bioscience. An ApopTag Red In Situ Apoptosis Detection kit S7165 was
purchased from Chemicon. All other reagents were obtained from Sigma (St. Louis, MO, USA).
4.2. Methods
4.2.1. Induction of Calcification
Rat VSMCs were obtained by enzymatic digestion, as previously described [25], and were routinely
subcultured in a growth medium (DMEM containing 10% FBS supplemented with 100 U/mL penicillin,
0.1 mg/mL streptomycin). At 80% confluence, cells were switched to the calcification medium (DMEM
containing 12% FBS supplemented with 100 U/mL penicillin, 0.1 mg/mL streptomycin, 10 mM sodium
pyruvate, and 50 µg/mL ascorbic acid) and challenged with 5mM Na3PO4 (Pi) for up to 15 days.
Ferric citrate (Fe) and H2O2 were added therapeutically on different days (7 or 9) after Pi challenge,
and samples treated with Fe or H2O2 or both, always in presence of Pi, were then processed at the final
time point required (day 11, 14, or 15). In H2O2 experiments on calcification, cells were stimulated
with 4.5 mM Pi. The medium was replaced every 2 or 3 days. Cells were used between the sixth and
eight passage.
To analyze the ex vivo calcification of rat aortic rings, we harvested aorta from female Lewis rats
(120-150 g). Briefly, after scraping adipose tissue from the adventitia, the cleaned aorta was cut into
3 mm-thick sections and stabilized in a growth medium for 24 h in petri dishes previously coated
with 100 µg/mL fibronectin. After stabilization, the medium was replaced with a calcification medium
(3 mM Pi) which was changed every 2 or 3 days up to day 14. Male Sprague-Dawley rats were kept in
accordance with guidelines from Directive 2010/63/EU of the European Parliament on the protection
of animals used for scientific purposes and the Italian Ministry of Health and the local University of
Milan ethics committee approved the protocol (NCT03169400; date of approval: 30 May 2017)
4.2.2. Quantification of Calcium Deposition and Alizarin Red Staining
The quantification of calcium deposition was performed by Alizarin Red S staining, followed by
HClO4 destaining. Extracellular calcium deposits were stained with an Alizarin Red S solution
for 30 minutes and destained for 24 h with 5% perchloric acid. The Ca content was determined
calorimetrically at a wavelength of 450nm. Protein content was quantified using a BCA protein
assay kit, and Ca deposition was normalized to protein content and expressed as absorbance (OD/mg
protein).
To visualize calcium deposition, cells were grown on plastic supports and, at the end of the
experiment, were fixed with 70% EtOH and stained with 1 mg/mL Alizarin Red S solution for 30 minutes.
Cells were rinsed and Ca deposition was photographed. The deposition of calcium salts by Alizarin
Red S staining was evaluated as the presence of fine granules (score 1) or large calcific deposits (score
2), or a confluent structure of calcium deposits (score 3); 0 was referred to as the absence of calcium
deposits; a.s. arbitrary score.
4.2.3. Western Blot
Rat VSMCs were harvested in an ice-cold homogenization buffer (50mM Tris pH 8 with 0.5%
IGEPAL CA-630, 1 mM phenylmethanesulfonyl fluoride (PMSF), 1mM benzamidine HCl, 1mM sodium
fluoride (NaF), 10mM β-glycerophosphate, and complete protease inhibitor), freeze-thawed 2X and
sonicated 5 × 20 s at 40% power. Samples were then centrifuged at 13,000 g for 15 minutes at 4 ◦C,
and the protein concentration was measured. Denatured samples (50 µg of total protein) were separated
by electrophoresis on a 12% (LC3-II), 7.5% (Axl and GAS6) SDS-polyacrylamide gel, and were then
transferred to the PVDF membrane. The membranes were incubated 1 h with 1:200 (Axl) or O/N with
1:100 (GAS6), 1:300 (LC3-II) primary antibodies, followed by 1 h incubation 1:10,000 (Axl and GAS6)
peroxidase-conjugated anti-goat or 1:20,000 (LC3-II) peroxidase-conjugated anti-rabbit secondary
antibodies. Protein bands were visualized using an ECL detection kit, and area intensity was measured.
Int. J. Mol. Sci. 2019, 20, 5925 14 of 15
4.2.4. Detection of Apoptosis
To evaluate apoptosis by cytofluorimetry with a PE Annexin V Apoptosis Detection Kit,
we disaggregated the VSMC multilayer. After two washes with warm PBS pH 7.4, we incubated the
sample with 1 ml of warm collagenase solution (5 mg/mL with 2.7 mM CaCl2) for 4 min at 37 ◦C.
Then, we added 1 ml of warm trypsin-EDTA solution (1×) for 1 min at 37 ◦C, and cells were gently
disaggregated mechanically. Successively, we washed and resuspended the cells at 750,000/sample to
be processed as indicated by the PE Annexin V Apoptosis Detection Kit I protocol. Briefly, VSCM cells
(750.000/sample) were resuspended in 1× Binding Buffer, 100 µL, and stained with 10 µL PE annexin V
and 10 µL 7-AAD for 30 min at room temperature in the dark. Following the addition of 0.4 mL of 1×
Binding Buffer, fluorescence of annexin V and 7-AAD were detected in the FL-2 and FL-3 channels,
respectively, within 1 h using a FACS Verse (BD Biosciences, Rockville, MD, USA). Unstained and
untreated cells were used to establish the instrument settings.
Apoptosis was also evaluated histologically by DNA fragmentation with the TUNEL technique,
both in cells and in aortic rings, with the ApopTag Red in situ Apoptosis Detection Kit, following
the manufacturer’s instructions. Apoptosis was detected as red signals mainly sited in the nuclei of
VSMCs. A few apoptotic bodies were also observed in the extracellular matrix and in the cytoplasm,
but only nuclear signals were considered in the present work. The number of apoptotic nuclei in 2
HPF (high power field, X40) was recorded for each experimental condition and scored as follows: 1:
<5% apoptotic nuclei, 2: <15% apoptotic nuclei; 3: <25% apoptotic nuclei; 4: ≥25% apoptotic nuclei.
4.2.5. Electron Microscopy
Samples of cells were scraped from culture flask, fixed in 2.5% glutaraldehyde in 0.13 M phosphate
buffer at pH 7.2–7.4 for 2 h, post-fixed in 1% osmium tetroxide, dehydrated through graded ethanol
and propylen oxide, and embedded in an epoxy resin. Ultrathin sections (50–60 nm thick) were
counterstained with uranyl acetate and lead citrate for observation with a Jeol JEM 1010 transmission
electron microscope (Jeol, Tokyo, Japan).
4.2.6. Statistical Analysis
The results were expressed as mean ± SEM. Each experiment was performed at least three times,
at least in triplicate. The differences between groups were analyzed by one-way ANOVA followed by
a Bonferroni post-hoc test, and were considered statistically significant when p value < 0.05. A score
statistical analysis was evaluated by a Kruskal-Wallis test, corrected for ties.
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